Wall Street analyst estimates for Drugs Made In America Acquisition II Corp. (DMIIR): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Drugs Made In America Acquisition II Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The company was founded on August 23, 2024 and is headquartered in Fort Lauderdale, FL.
Valuation Ratios
| P/E Ratio | 0.40 |
| Price / Book | 0.01 |
| EV / EBITDA | -5.24 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2024 | 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Research & Development | 0 | 0 |
| Selling, General & Admin | $151719 | $1.3M |
| Operating Expenses | $151719 | $1.3M |
| Operating Income | -$151719 | -$1.3M |
| EBITDA | -$151719 | -$1.3M |
| Interest Expense | 0 | 0 |
| Pre-tax Income | -$151719 | $4.2M |
| Income Tax | 0 | 0 |
| Net Income | -$151719 | $4.2M |
| EPS | $-0.00 | $0.07 |
| EPS (Diluted) | $-0.00 | $0.07 |
| Shares Outstanding (Diluted) | $63.7M | $64.4M |
Price
| Price | $0.07 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | US |
Explore sector: Financial Services · Financial - Conglomerates
More sections of DMIIR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks